Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals, Inc. - Common Stock
(NQ:
ALNY
)
397.65
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alnylam Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
December 17, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
December 11, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Announces Changes to Board of Directors
December 03, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
November 08, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
November 04, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
October 30, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
October 16, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
October 01, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
September 29, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
September 09, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
September 08, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM
August 31, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
August 30, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
August 27, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025
August 11, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
August 05, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress
July 31, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
July 17, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
June 18, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
June 11, 2025
From
Instil Bio
Via
GlobeNewswire
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
June 09, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
May 28, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Issues 2024 Corporate Responsibility Report
May 20, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
May 17, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
May 12, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
May 05, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
May 01, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
April 28, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
April 17, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
April 01, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
